Germany’s lower parliament has voted to advance a cost-saving bill that would raise mandatory rebates on most brand-name prescription drugs from 7% to 15.5%, affecting manufacturer net pricing across a broad swath of portfolios. The legislation also includes a vaccine discount increase to 9% and extends a price freeze for vaccines from January 2027 through December 2030. The measure, known as GKV-BStabG, now moves to Germany’s upper parliament stage. Industry groups have criticized the bill, while the policy also raises the profile of value and cost-effectiveness scrutiny and could increase competition for tender-style rebate contracts. For biopharma, the development adds near-term regulatory and commercial planning pressure, particularly for companies that rely on price adjustments to offset inflation and R&D cost trajectories.